Results 111 to 120 of about 11,499 (250)

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential

Vascular Health and Risk Management, 2008
Nasser MikhailEndocrinology Division, Olive View-UCLA Medical Center, David-Geffen School of Medicine, CA, USAAbstract: Sitagliptin and vildagliptin represent a new class of anti-diabetic agents that enhance the action of incretin hormones through ...
Nasser Mikhail
doaj  

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin / metformin, Diabetes Mellitus, Type 2, Date of authorisation: 30/11/2008, Revision: 19, Status: Authorised [PDF]

, 2018
Kernel Networks Inc.
openalex   +1 more source

Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience

Vascular Health and Risk Management, 2010
James E Foley1, Jens Jordan21Clinical Research and Development, Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA; 2Institute for Clinical Pharmacology, Hannover Medical School, Hannover, GermanyAbstract: Various factors may confound how
James E Foley, Jens Jordan
doaj  

Ameliorative influence of vildagliptin on genetic model of neurodegenerative diseases in Drosophila melanogaster

, 2021

openalex   +1 more source

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

Vascular Health and Risk Management, 2011
Anja Schweizer1, Sylvie Dejager2, James E Foley3, Wolfgang Kothny31Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharma SAS, Rueil-Malmaison, France; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAAim: Analyzing safety aspects of a drug ...
Schweizer A, Dejager S, Foley JE, Kothny W   +3 more
doaj  

Vildagliptin promotes diabetic foot ulcer healing through autophagy modulation

Diabetology & Metabolic Syndrome
The study aimed to investigate the molecular mechanisms underlying the effects of Vildagliptin on the healing of diabetic foot ulcers (DFUs). The research compared patients who received 12 weeks of Vildagliptin treatment to those who did not.
Erik Biros, Venkat Vangaveti, Usman Malabu   +2 more
doaj   +1 more source

Safety and efficacy of vildagliptin-metformin to glimepiride-metformin in type 2 diabetes mellitus patients - A comparative study

, 2019
P Selvi, D Nishanthini
openalex   +1 more source

Emerging role of insulin with incretin therapies for management of type 2 diabetes [PDF]

, 2011
Rupa Ahluwalia, Jiten Vora
core   +1 more source

Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients

, 2021
Surendra Kumar
openalex   +1 more source

A comparative study on vildagliptin brand and its generic equivalents using dissolution test as quality control measure tool

Scientific Reports
Market drugs including brand or generic with poor quality, don’t meet the acceptable standard guidelines. Vildagliptin is an important antidiabetic drugs used in monotherapy or in combinations protocols for treatment of diabetes mellites.
Ghadah H. Altoum, Fouza K. AL-Enazi, Mubarl M. Abudahash, Reem A. AL-Fadhli, Naif Alenzi   +4 more
doaj   +1 more source